Akèy › Myelom miltip k ap boukante
Etid klinik pou Myelom miltip k ap boukante ap rekrite nan Etazini
20 etid pou Myelom miltip k ap boukante ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Boston, MA6 etid
- New York City, NY6 etid
- Atlanta, GA5 etid
- Columbus, OH3 etid
- Edison, NJ3 etid
- Denver, CO3 etid
- Houston, TX3 etid
- Salt Lake City, UT3 etid
- Durham, NC3 etid
Pa eta
- Colorado3 etid
- Florid4 etid
- Georgia5 etid
- Massachusetts6 etid
- Michigan4 etid
- New Jersey3 etid
- New York8 etid
- North Carolina4 etid
- Ohio3 etid
- Texas4 etid
- Utah3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07393282A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06768489Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT03937635Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT05469893CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 30 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT06644625A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 8, 2026 · NCT06140524Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 1, 2026 · NCT04776395Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 7, 2026 · NCT02269592FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 1, 2026 · NCT07446777Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 21, 2026 · NCT02726750A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT05640843Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT05136807Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT05361694Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 17, 2026 · NCT06212323Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Dec 1, 2025 · NCT05312255Registry for Adults With Plasma Cell Disorders (PCD's)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Nov 20, 2025 · NCT03717844A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Nov 13, 2025 · NCT06055894The Indiana Myeloma Registry
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Nov 10, 2025 · NCT03616483Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Ap rekriteEtid obsèvasyon
Laj 40 ak plis · Tout sèks · Mizajou Aug 6, 2025 · NCT06365060Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 10, 2025 · NCT05597345Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.